newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference

  • Ascentage Pharma Group International announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, at 2:15 p.m. PT.
  • The company is a global, commercial-stage biopharmaceutical entity focused on discovering & commercializing therapies for cancer, including Bcl-2 & MDM2-p53 inhibitors & next-generation kinase inhibitors.
  • Olverembatinib is the company's first approved product in China as a third-generation BCR-ABL1 inhibitor for CML patients with T315I mutations or resistance to prior TKIs, with all indications covered by the China National Reimbursement Drug List.
  • A global registrational Phase III trial (POLARIS-2) for Olverembatinib in CML is underway, alongside Phase III trials for newly diagnosed Ph+ ALL & SDH-deficient GIST.
  • Lisaftoclax is the second approved product, a Bcl-2 inhibitor for CLL/SLL patients previously treated with BTK inhibitors in China.
  • Four global registrational Phase III trials for Lisaftoclax are active: GLORA (combination with BTK inhibitors in refractory CLL/SLL), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (elderly/unfit AML), & GLORA-4 (higher-risk MDS).
  • The GLORA-4 study received clearance from the US FDA, EU EMA, & China CDE simultaneously.
  • The company maintains global partnerships with Takeda, AstraZeneca, Merck, Pfizer, & Innovent, plus research ties with Dana-Farber, Mayo Clinic, NCI, & University of Michigan.
  • The press release includes forward-looking statements subject to risks & uncertainties detailed in the company's SEC filings.
  • Investor & media contacts include Stella Yang, Stephanie Carrington, & Sean Leous.